Valirx (VAL)

 

VAL Share PerformanceMore

52 week high11.4900 04/10/16
52 week low2.0600 05/04/17
52 week change -7.6000 (-76.00%)
4 week volume14,643,545 01/05/17

Media for (VAL)

Presenter: Dr Satu Vainikka
08/05/2017
Presenter: ValiRx Management Team
08/03/2017

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ValiSeek's patent allowed in Australia

ValiRx reported that ValiSeek, the joint venture between ValiRx and Tangent Reprofiling, received notification that an Au...

NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE

RNS Number: 0240G ValiRx PLC 24 May 2017 ValiRx Plc ("ValiRx" or the "Company") NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE FOR THERAPEUTIC COMPOUND, VAL401 London, UK ., 24 May 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to report that ValiSeek Limited ("ValiSeek"), the joint venture...

Broker Forecast - Beaufort Securities issues a broker note on ValiRx PLC

Beaufort Securities today reaffirms its speculative buy investment rating on ValiRx PLC (LON:VAL) and set its price targ...

ValiRx - Final Results

Notice of AGM

RNS Number: 3902E ValiRx PLC 05 May 2017 ValiRx Plc ("ValiRx" or the "Company") Posting of Annual Report and Accounts & Notice of Annual General Meeting London, UK, 5 May 2017: ValiRx Plc (AIM: VAL) is a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine. The Company announces that its Annual Rep...

ValiRx widens FY pretax loss from continuing ops.

ValiRx has widened its FY pretax loss from continuing operations to 5.8m, which was more than double the prior year's lo...

Final Results

RNS Number: 2546E ValiRx PLC 05 May 2017 VALIRX PLC ("ValiRx", "the Company" or "the Group") FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2016 London, UK, 5 May 2017: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine, today announces its final results for the ...

Re: SHARES Magazine Supplement on ValiRx website

RNS Number: 5389D ValiRx PLC 27 April 2017 VALIRX PLC ("ValiRx", "the Company") Re: The SHARES Magazine Supplement " ValiRx And The Drug Development Journey", is now available on the ValiRx website London, UK., 27 April 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to report that a recent supplement on the ...

Fundamental DataMore

EPS-8.54
Dividend yield0 %

Equity Research (VAL)

edison investment research
ValiRx plc
20/01/2015
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...

Latest discussion posts More

Users' HoldingsMore

Users who hold Valirx also hold..
ROCKHOPPER18%
RANGE RES.17%
LLOYDS GRP.17%
SOUND ENERGY16%
SAREUM15%

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL